drugset / Trial / NCT05232552
Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Background | DDP | Unknown | 75 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |